Sekungamashumi amabili eminyaka, i-albendazole inikelwe ohlelweni olukhulu lokwelapha i-lymphatic filariasis. Ukubuyekezwa okubuyekeziwe kwe-Cochrane kuhlole ukusebenza kwe-albendazole ku-lymphatic filariasis.
I-Lymphatic filariasis isifo esithwalwa omiyane esivame ukutholakala ezindaweni ezishisayo nezishisayo esibangelwa ukutheleleka kwe-parasitic filariasis. Ngemva kokutheleleka, izibungu zikhula zibe abantu abadala futhi zihlangane zenze i-microfilariae (mf). I-MF ibe iqoqwa omiyane ngenkathi idla igazi, futhi ukutheleleka kungadluliselwa komunye umuntu.
Ukutheleleka kungatholwa ngokuhlolwa kokujikeleza kwe-MF (microfilaraemia) noma ama-antigen ezinambuzane (i-antigenemia) noma ngokutholwa kwezikelemu zabantu abadala nge-ultrasound.
I-World Health Organization (WHO) incoma ukwelashwa kwabantu abaningi ngonyaka okungenani iminyaka emihlanu. Isisekelo sokwelashwa siyinhlanganisela yezidakamizwa ezimbili: i-albendazole kanye ne-microfilaricidal (antimalarial) drug diethylcarbamazine (DEC) noma ivermectin.
I-Albendazole inconywa njalo ngonyaka ezindaweni lapho i-loiasis ihambisana khona, futhi i-DEC noma i-ivermectin akufanele isetshenziswe ngenxa yengozi yemiphumela emibi kakhulu.
Kokubili i-ivermectin ne-DEK kususe ukutheleleka kwe-mf ngokushesha futhi kunganqanda ukuphindeka kwakho. Nokho, ukukhiqizwa kwe-mf kuzophinda kuqalise ngenxa yokuchayeka okulinganiselwe kubantu abadala. I-Albendazole yacatshangelwa ukwelashwa kwe-lymphatic filariasis ngoba ucwaningo lwabika ukuthi imithamo ephezulu esetshenziswa emasontweni ambalwa ibangele imiphumela emibi ephakamisa ukufa kwezikelemu ezindala.
Umbiko ongakahleleki wokubonisana kwe-WHO kamuva waphakamisa ukuthi i-albendazole inomphumela wokubulala noma wokubulala isikhunta kubantu abadala. Ngo-2000, i-GSK yaqala ukunikela nge-albendazole ohlelweni lweLymphatic Filariasis Treatment Programme.
Izivivinyo zemitholampilo ezingahleliwe (RCTs) zihlole ukusebenza kahle nokuphepha kwe-albendazole yedwa noma kuhlanganiswe ne-ivermectin noma i-DEC. Lokhu kuye kwalandelwa ukubuyekezwa okuhlelekile okuningana kwama-RCT kanye nedatha yokubuka, kodwa akucaci ukuthi i-albendazole inenzuzo yini ku-lymphatic filariasis.
Ngenxa yalokhu, ukubuyekezwa kwe-Cochrane okushicilelwe ku-2005 kuye kwabuyekezwa ukuze kuhlolwe umthelela we-albendazole kubantu kanye nemiphakathi ene-lymphatic filariasis.